Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Senti Biosciences, Inc. SNTI
$0.95
-$0.04 (-4.12%)
На 17:51, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
46818080.00000000
-
week52high
9.99
-
week52low
0.94
-
Revenue
4286000
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-2.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мар 2023 г. в 21:09
Описание компании
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 23 сент 2022 г. | |
| B of A Securities | Buy | 29 сент 2022 г. | |
| Morgan Stanley | Equal-Weight | 07 окт 2022 г. | |
| JP Morgan | Neutral | 16 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lu Timothy K | A | 630000 | 630000 | 01 февр 2023 г. |
| Rajangam Kanya | A | 130000 | 130000 | 01 февр 2023 г. |
| KNOBELMAN DEBORAH | A | 130000 | 130000 | 01 февр 2023 г. |
| Lee Philip J | A | 195000 | 195000 | 01 февр 2023 г. |
| KNOBELMAN DEBORAH | A | 240000 | 240000 | 03 окт 2022 г. |
| KNOBELMAN DEBORAH | A | 30000 | 30000 | 03 окт 2022 г. |
| Rajangam Kanya | A | 327750 | 327750 | 18 июл 2022 г. |
| Mathers Edward T | A | 125000 | 125000 | 13 июл 2022 г. |
| COOPERSTONE BRENDA | A | 125000 | 125000 | 13 июл 2022 г. |
| Epstein David R | A | 125000 | 125000 | 13 июл 2022 г. |
Новостная лента
Senti Bio to Present at the SVB Securities Global Biopharma Conference
GlobeNewsWire
01 февр 2023 г. в 16:05
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti's Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference.
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
19 дек 2022 г. в 07:55
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 5:15 p.m. PT.
Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
GlobeNewsWire
03 ноя 2022 г. в 09:05
Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting
GlobeNewsWire
05 окт 2022 г. в 08:01
Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors Abstracts highlight Senti Bio's continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors
Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today
PennyStocks
30 сент 2022 г. в 06:00
Here's what you need to know about buying penny stocks on September 29th The post Best Penny Stocks to Buy in a Volatile Market? 3 to Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.